Ampersand Capital Partners Acquires and Merges Peptides International with New England Peptide to Strengthen Global Peptide Synthesis Leadership

VCBeat (WeChat ID: vcbeat) has learned that on December 16, 2019, local time, Ampersand Capital Partners announced the completion of its acquisition of Peptides International and its merger with existing portfolio company New England Peptide. This merger brings together two leading peptide synthesis service providers and their extensive catalogs of unique peptide products to support drug discovery and diagnostic product development efforts worldwide.

Headquartered in Louisville, Kentucky, USA, and founded in 1983, Peptides International is a global leader in custom peptide production, providing high-quality peptide synthesis services to numerous pharmaceutical, biotechnology, and other life sciences customers. Peptides International is dedicated to tackling the most complex peptide synthesis projects and offering clients comprehensive chemical optimization and scale-up services.

“New England Peptide is pleased to announce that we have completed our merger with Peptides International, marking 20 years as a custom peptide synthesis company,” said Sam Massoni, CEO of New England Peptide. “This transaction adds meaningful scale, high-quality customer relationships, and a strong market reputation to the foundation we have built at New England Peptide.”

Jackie Spatola, CEO of Peptides International, added, “The acquisition of Peptides International by Ampersand Capital Partners has accelerated the growth of the high-quality custom peptide market, reinforcing our strategic position as a global leader with a 35-year legacy. We look forward to enhancing our service quality and building a larger global customer base through our collaboration with New England Peptide.”

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. Ampersand maintains offices in Boston, Massachusetts, and Amsterdam, the Netherlands. Leveraging its unique private equity and operational expertise, Ampersand has built a robust portfolio of companies in the healthcare industry, including Avista Pharma Solutions, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories.

New England Peptide, founded in 1998, designs and manufactures peptide and antibody solutions for global drug, vaccine, and diagnostic development organizations. Headquartered in Gardner, Massachusetts, the company specializes in custom peptide synthesis, polyclonal antibody production, stable-labeled bioanalytical peptide standards, and catalog peptide products. New England Peptide operates from a 25,000-square-foot facility with extensive laboratory space to meet all customer and regulatory requirements.

(Compiled by Ning Chen)